10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. More Details
High growth potential with excellent balance sheet.
Share Price & News
How has 10x Genomics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TXG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: TXG's weekly volatility (9%) has been stable over the past year.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: TXG exceeded the US Life Sciences industry which returned 41.9% over the past year.
Return vs Market: TXG exceeded the US Market which returned 36.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is 10x Genomics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs 10x Genomics, Inc.'s (NASDAQ:TXG) Shareholder Ownership Skewed Towards Insiders?
1 month ago | Simply Wall StHave Insiders Been Selling 10x Genomics, Inc. (NASDAQ:TXG) Shares?
2 months ago | Simply Wall StInvestors Who Bought 10x Genomics (NASDAQ:TXG) Shares A Year Ago Are Now Up 76%
Is 10x Genomics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: TXG ($183.47) is trading above our estimate of fair value ($28.07)
Significantly Below Fair Value: TXG is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TXG is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: TXG is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TXG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TXG is overvalued based on its PB Ratio (26.7x) compared to the US Life Sciences industry average (5.8x).
How is 10x Genomics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TXG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: TXG is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TXG's is expected to become profitable in the next 3 years.
Revenue vs Market: TXG's revenue (24.9% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: TXG's revenue (24.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TXG is forecast to be unprofitable in 3 years.
How has 10x Genomics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TXG is currently unprofitable.
Growing Profit Margin: TXG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TXG is unprofitable, and losses have increased over the past 5 years at a rate of 77.4% per year.
Accelerating Growth: Unable to compare TXG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TXG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.8%).
Return on Equity
High ROE: TXG has a negative Return on Equity (-70.85%), as it is currently unprofitable.
How is 10x Genomics's financial position?
Financial Position Analysis
Short Term Liabilities: TXG's short term assets ($745.7M) exceed its short term liabilities ($120.5M).
Long Term Liabilities: TXG's short term assets ($745.7M) exceed its long term liabilities ($81.0M).
Debt to Equity History and Analysis
Debt Level: TXG is debt free.
Reducing Debt: TXG had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TXG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TXG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is 10x Genomics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TXG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TXG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TXG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TXG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Serge Saxonov (44 yo)
Dr. Serge Saxonov, Ph.D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
CEO Compensation Analysis
Compensation vs Market: Serge's total compensation ($USD10.88M) is about average for companies of similar size in the US market ($USD11.26M).
Compensation vs Earnings: Serge's compensation has increased whilst the company is unprofitable.
Experienced Management: TXG's management team is considered experienced (3.6 years average tenure).
Experienced Board: TXG's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TXG insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.6%.
10x Genomics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: 10x Genomics, Inc.
- Ticker: TXG
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$20.145b
- Shares outstanding: 109.80m
- Website: https://www.10xgenomics.com
Number of Employees
- 10x Genomics, Inc.
- 6230 Stoneridge Mall Road
- United States
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, a...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/24 00:40|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.